急性腎障礙 (AKI) - KOL的考察，競爭情報，市場分析、預測 (∼2030年)
Acute Kidney Injury (AKI) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
|出版商||Mellalta Meets LLP||商品編碼||997045|
|出版日期||內容資訊||英文 137 Pages
|急性腎障礙 (AKI) - KOL的考察，競爭情報，市場分析、預測 (∼2030年) Acute Kidney Injury (AKI) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2030|
|出版日期: 2020年11月30日||內容資訊: 英文 137 Pages||
2019年的主要市場上急性腎障礙 (AKI) 和確診的病例數，是約195萬人。由於人口動態的變化和急性腎障礙 (AKI)的相關疾病的病例數增加，預計2030年病例數超過208萬人。
本報告提供急性腎障礙 (AKI) 市場相關調查分析，市場趨勢，G7病例數，市場機會，市場預測，競爭分析等相關的系統性資訊。
Growth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $5.2 billion by 2030.
Acute kidney injury - AKI is common in hospitalized adults and children and associated with serious complications and high health care costs. Being hospitalized, especially for a serious condition that requires intensive care, advanced age, blockages in the blood vessels in arms or legs (peripheral artery disease), diabetes, high blood pressure, heart failure, kidney diseases, liver diseases, certain cancers and their treatments are the major causative factors that contributes to the incidence of AKI between different countries.
Mellalta Meets has adopted the findings from a meta-analysis study conducted by International Society of Nephrology's 0by25 initiative for acute kidney injury (Ravindra L Mehta, 2015). In the base year of our study period, we estimate an AKI prevalence of 275 per million people in Japan, 1811 per million in the five European markets covered in this report (France, Germany, Italy, Spain, and the United Kingdom), and 3000-5000 per million in the United States. The reported studies from high-income countries are focused on studies that defines AKI on the basis of the RIFLE, AKIN, and KDIGO diagnostic criteria, because they allow a more accurate ascertainment of the incidence and outcomes of AKI in high-income countries, therefore, we expect 100% diagnosis rate. Therefore. We hold our diagnosed and treatment cases estimates constant over the forecast period, and changes in the number of AKI cases are due to demographic shifts.
The Acute Kidney Injury (AKI) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2019 to $XX billion in 2030, representing 2.6% annual growth. Primary drivers of this growth will be uptake of the novel 6 months treatment i.e. Refanalin (Angion), teprasiran (Quark/Novartis), bRESCAP (Alloksys), recAP (AM Pharma), Conestat alfa (Pharming) and ASP-1128 (Astellas), along with an expanding number of AKI cases associated with sepsis, Cardiac surgery and contrast induced angiography (CIN), CIVID-19 associated AKI and delayed graft function (DGF), predominantly in the United States.
Most interviewed experts believe, that patients will benefit from the upcoming therapies launching in the Sepsis-associated AKI (SA-AKI), Cardiac Surgery associated AKI (CSA-AKI) and others including, delayed graft function and for the prevention of the contrast induced AKI (CA-AKI) in coronary angiography. Refanalin(Angion) will be the first therapy which will be launched in the market for CSA-AKI and will have first mover advantage over other therapies which are launching in same space such as teprasiran (Quark/Novartis), ASP-1128 (Astellas) and bRESCAP (Alloksys). We also believe that the drug will begin facing competition with its peer therapies as physicians' preference for these agents in terms of knowledge of efficacy and safety grows.